Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:08:30.943Z.
Calculation as of: 2026-10-06T17:08:30.943Z.
Quote observation: 2026-10-06T17:03:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8d1468b7a76ea597d68349990a611a16a2ef6f087c77b10e193910d6856baa6d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $29.37M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.33M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.50M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.95M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.00M | N/A | 0.36x | 0.82x | 0.82x |
| BeyondSpring Inc. (BYSI)vs › | $30.34M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.49M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.59M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.74M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $31.12M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute